Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy

Clinical Infectious Diseases

Volumn 50, Issue 1, 2010, Pages 85-92

  Hage, Chadi A ^a   Bowyer, Suzanne ^b   Tarvin, Stacey E ^b   Helper, Debra ^b   Kleiman, Martin B ^b   Wheat, L Joseph ^c  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MIRAVISTA DIAGNOSTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; ETANERCEPT; FLUCONAZOLE; INFLIXIMAB; ITRACONAZOLE; VORICONAZOLE;

ANTIGEN DETECTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RISK; LUNG LAVAGE; MORBIDITY; MORTALITY; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT EDUCATION; PNEUMONIA; PRIORITY JOURNAL; RECIPIENT; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; FEMALE; HISTOPLASMA; HISTOPLASMOSIS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; MIDDLE AGED; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 72049096147     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648724     Document Type: Review

References (49)

1. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008; 46:1738-1740 (Pubitemid 351706773)
2. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor-a blockade therapy. Mayo Clin Proc 2008; 83:181-194 (Pubitemid 351303102)
3. US Food and Drug Administration. Information for healthcare professionals: cimzia (certolizumab pegol), enbrel (etanercept), humira (adalimumab), and remicade (infliximab). 4 September 2008. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafety informationforpatientsandproviders/ucm124185.htm. Accessed 13 November 2009.
4. Frank KM, Hogarth DK, Miller JL, et al. Investigation of the cause of death in a gene-therapy trial. N Engl J Med 2009; 361:161-169
5. Cutler JE, Deepe GS Jr, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007; 5:13-28.
6. Deepe GS Jr, Gibbons RS. T cells require tumor necrosis factor-a to provide protective immunity in mice infected with Histoplasma capsulatum. J Infect Dis 2006; 193:322-330
7. Zhou P, Miller G, Seder RA. Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-a plays a critical role in maintaining secondary immunity in the absence of IFN-g. J Immunol 1998; 160:1359-1368
8. Allendoerfer R, Deepe GS Jr. Regulation of infection with Histoplasma capsulatum by TNFR1 and-2. J Immunol 2000; 165:2657-2664
9. Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-a exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 1998; 160:6072-6082 (Pubitemid 28298071)
10. Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005; 41(Suppl 3):S194-8.
11. Deepe GS Jr. Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-a activity. Clin Infect Dis 2005; 41(Suppl 3):S204-7.
12. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-1265 (Pubitemid 38608568)
13. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor-a-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58:1248-1257 (Pubitemid 351705913)
14. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969; 99:1-18.
15. Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis 2002; 4:148-151 (Pubitemid 35364779)
16. Hughes WT. Hematogenous histoplasmosis in the immunocompromised child. J Pediatr 1984; 105:569-575
17. Wheat LJ, Smith EJ, Sathapatayavongs B, et al. Histoplasmosis in renal allograft recipients. Two large urban outbreaks. Arch Intern Med 1983; 143:703-707
18. Straub M, Schwarz J. The healed primary complex in histoplasmosis. Am J Clin Pathol 1955; 25:727-741
19. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005; 41(Suppl 3):S199-203.
20. Goulet CJ, Moseley RH, Tonnerre C, Sandhu IS, Saint S. Clinical problem- solving. The unturned stone. N Engl J Med 2005; 352:489-494
21. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor-a antagonists infliximab and etanercept. Arthritis Rheum 2002; 46:2565-2570
22. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-TNF-a therapy. Am J Respir Crit Care Med 2003; 167:1279-1282
23. Sawalha AH, Lutz BD, Chaudhary NA, Kern W, Harley JB, Greenfield RA. Panniculitis: a presenting manifestation of disseminated histoplas mosis in a patient with rheumatoid arthritis. J Clin Rheumatol 2003; 9: 259-262 (Pubitemid 36961203)
24. Galandiuk S, Davis BR. Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5:283-287 (Pubitemid 351637914)
25. Zhang Z, Correa H, Begue RE. Tuberculosis and treatment with in- fliximab. N Engl J Med 2002; 346:623-626
26. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002; 112:78-79
27. Jain VV, Evans T, Peterson MW. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor-a in a patient from a nonendemic area. Respir Med 2006; 100:1291-1293 (Pubitemid 43793058)
28. Narayana N, Gifford R, Giannini P, Casey J. Oral histoplasmosis: an unusual presentation. Head Neck 2009; 31:274-277
29. Zaman R, Abbas M. Case report of fatal disseminated histoplasmosis in a patient with rheumatoid arthritis following therapy with etanercept and methotrexate. In: Program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America (Chicago). 2002. Abstract 378.
30. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:889-894
31. Asrani NS. Disseminated histoplasmosis associated with the treatment of rheumatoid arthritis with anticytokine therapy. Ann Intern Med 2008; 149:594-595
32. Yan TD, Kavuru MS, Yen-Lieberman B, Brzezinski A, Gordon SM. Immune function evaluation (ImmuKnow Assay) in a patient treated with infliximab who develop miliary histoplasmosis. Infect Dis Clin Pract 2005; 13:315-317 (Pubitemid 41689686)
33. Ankobiah WA, Vaidya K, Powell S, et al. Disseminated histoplasmosis in AIDS. Clinicopathologic features in seven patients from a nonendemic area. N Y State J Med 1990; 90:234-238 (Pubitemid 20152685)
34. Sathapatayavongs B, Batteiger BE, Wheat J, Slama TG, Wass JL. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983; 62:263-270
35. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculinspecific Th1-responses induces immune restoration syndrome in tuberculosis and HIV coinfected patients. AIDS 2006; 20:F1-7.
36. Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 2005; 9:1057-1058
37. Egan L, Connolly PA, Fuller D, et al. Detection of Histoplasma capsulatum antigenuria by ultrafiltration of samples with false-negative results. Clin Vaccine Immunol 2008; 15:726-728
38. Swartzentruber S, LeMonte A, Witt J, et al. Improved detection of Histoplasma antigenemia following dissociation of immune complexes. Clin Vaccine Immunol 2009; 16:320-322
39. Koduri PR, Chundi V, Demarais P, Mizock BA, Patel AR, Weinstein RA. Reactive hemophagocytic syndrome: a new presentation of disseminated histoplasmosis in patients with AIDS. Clin Infect Dis 1995; 21:1463-1465 (Pubitemid 26066639)
40. De Lavaissiere M, Manceron V, Bouree P, et al. Reconstitution inflammatory syndrome related to histoplasmosis, with a hemophagocytic syndrome in HIV infection. J Infect 2009; 58:245-247
41. Nacher M, Sarazin F, El Guedj M, et al. Increased incidence of disseminated histoplasmosis following highly active antiretroviral therapy initiation. J Acquir Immune Defic Syndr 2006; 41:468-470 (Pubitemid 43756163)
42. Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis 2008; 46:1426-1433 (Pubitemid 351589944)
43. LeMonte A, Egan L, Connolly P, Durkin M, Wheat LJ. Evaluation of the IMMY ALPHA histoplasma antigen enzyme immunoassay for diagnosis of histoplasmosis marked by antigenuria. Clin Vaccine Immunol 2007; 14:802-803
44. Hage CA, Davis TE, Egan L, et al. Diagnosis of pulmonary histoplasmosis and blastomycosis by detection of antigen in bronchoalveolar lavage fluid using an improved second-generation enzyme-linked immunoassay. Respir Med 2007; 101:43-47 (Pubitemid 44835243)
45. Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther 2006; 6:1207-1221
46. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 807-825
47. Mayanja-Kizza H, Jones-Lopez E, Okwera A, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005; 191:856-865 (Pubitemid 40349799)
48. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18:257-264 (Pubitemid 38253448)
49. Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008; 47:e83-5.